Skip to content
GLP-1 Desk
Menu
Dispatch #11

Gala Health

One of the few desks that pairs a genuine brand-name path with low compounded entry pricing across all 50 states.

Visit Gala HealthAssume any provider we list may compensate us — it never changes the Desk Score.
Semaglutide
$1,299/mo (brand Ozempic)
Tirzepatide
$179/mo
Coverage
All 50 states
Brand-name
Yes

Weigh Gala Health against the full ranked field on the best semaglutide providers board, or line it up against its closest alternatives.

Desk Score breakdown

Each of the six scored dimensions. See the methodology.

Price transparency86/100
State access96/100
Molecule range90/100
Onboarding speed82/100
Support responsiveness80/100
Licensing & trust82/100

What the Desk likes

  • Low compounded entry — tirzepatide $179/mo and a $149/mo microdose tier
  • Real brand-name Ozempic path alongside compounded
  • Nationwide 50-state coverage
  • Adjacent HRT/menopause line for broader care

Where points come off

  • Compounded formulations are not FDA-approved
  • Brand-name Ozempic is very expensive at $1,299/mo — compounded is the realistic route
  • No oral or sublingual route yet
  • Newer operator with a shorter track record

The Desk's briefing — B

Best for: Patients who want a low compounded starting price but value having a real brand-name Ozempic option on the same account.

Gala Health ranks #11 of 30 providers scored — see #1, CoreAge Rx on the board.

Related dispatches

Pricing and verification reflect Gala Health's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on Gala Health's site. Not medical advice; see our disclosure.

← Back to The Desk